Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies

By afschroeder • May 27, 2026

Maron SB, Xu RH, Wainberg ZA, Rha SY, Zhang Y, Pietrantonio F, Oliveira SCS, Li Y, Chen MH, Korphaisarn K, Elimova E, Calderon CA, Herpe FV, Yong WP, Dos Santos TM, Tan M, Isse K, Yanes RE, Shitara K. Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies. ESMO Open. 2026 May 26;11(6):107698. doi: 10.1016/j.esmoop.2026.107698. Epub ahead of print. PMID: 42190313.

Tags: Biomarker, fibroblast growth factor receptor 2 isoform IIIb, gastric cancer, gastroesophageal junction cancer, Hematology/Oncology, immunohistochemistry, Publications

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer

Sayar E, Richards HM, Gulati R, Patel RA, Hanratty B, Lee HJ, Coleman I, Mustafi P, Ding CC, Chen WS, Quigley D, Setty M, Lang[...]

Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249

Kuroki LM, Enserro DM, Lankes HA, Strickland KC, Previs R, Clements A, Powell MA, Klopp A, Ratner E, DiSilvestro P, Cosgrove C, Cantuaria GH, Spirtos[...]

A Presumed Metastatic Lung Lesion Unveiling a Second Primary: Renal Cell Carcinoma With Coinciding Invasive Mucinous Adenocarcinoma

Dao KT, Singh S, Kaloty P, Bandak D, Yasonova M, Dhillon H, Singh C, Montana W. A Presumed Metastatic Lung Lesion Unveiling a Second Primary:[...]